CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Sign up today and learn more about CRISPR Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Funding History
April 2014 | $25.0M |
---|---|
April 2015 | $64.0M |
June 2016 | $38.0M |
Management
Scientific Founders
Daniel Anderson
Scientific Founders
Emmanuelle Charpentier
Founder & CFO
Shaun Foy
Founder & Chief Executive Officer
Rodger Novak
Scientific Founders
Craig Mello
Chief Scientific Officer
Bill Lundberg
Scientific Founders
Chad Cowan
Scientific Founders
Matthew Porteus
Press
Forbes - Nov, 19 2019
New Data From First Human Crispr Trials Shows Promising ResultsTechCrunch - Nov, 26 2018
Hospital in China denies links to world’s first gene-edited babiesTechCrunch - Nov, 25 2018
UPDATED: CRISPR scientist in China claims his team’s research has resulted in the world’s first gene-edited babiesNasdaq Place (press release) - Jun, 26 2018
Most Active Stock to Track: CRISPR Therapeutics AG (CRSP)StreetInsider.com - Jun, 16 2018
Form 4 CRISPR Therapeutics AG For: Jun 15 Filed by: Kulkarni Samarth